Previous 10 | Next 10 |
From the Big Picture to Individual Stock Breakouts Last year I highlighted the Healthcare Biotech Sector Breakout and correctly forecasted "at least 20% gains in sector ETFs and even higher for many key biotech stocks in the near term." I believe the technical analysis that I will det...
Every month, this is my favorite article to sit down and write. That's because the first thing I have to do when getting started is log into my brokerage accounts and tally up the prior month's dividends. Adding these totals into my long-term dividend appreciation chart provides concrete evide...
Celgene ( CELG +0.3% ) has filed a marketing application with the FDA seeking approval for luspatercept for the treatment of adult patients with very-low-to-intermediate-risk myelodysplastic syndromes-associated anemia who have ring sideroblasts and require red blood cell transfusions an...
BLA submission includes both myelodysplastic syndromes and beta-thalassemia indications EMA marketing application for both indications planned for Q2:19 Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that Celgene has submitted a Biol...
AVROBIO (NASDAQ: AVRO ) initiated with Buy rating at Janney Montgomery Scott. More news on: AVROBIO, Inc., Amicus Therapeutics, Inc., Celgene Corporation, Healthcare stocks news, Stocks on the move, , Read more ...
In contrast to the end of 2018, 2019 has brought new life into the markets. The S&P 500 has gained 13% for the quarter, recovering over 90% of the December dip and now sitting just about 3% off of all-time highs. Source: WSJ Earning season will be kicking off in mid-April. Current expe...
Celgene ( CELG ) had achieved a highly positive outcome because it was able to refile its NDA application for its multiple-sclerosis drug Ozanimod. This move comes a year after the biotech suffered a major setback with its first submission in 2018. This is an important milestone for the biot...
Roche ( OTCQX:RHHBY +0.3% ) announces positive data from an open-label Phase 1b clinical trial evaluating the combination of ipatasertib, Tecentriq (atezolizumab) and Celgene's ( CELG -0.9% ) Abraxane (paclitaxel albumin-bound particles for injectable suspension) for the first-line tre...
This article explains the reasons behind the movement in a selection of the largest U.S. cash merger arbitrage spreads from the past week as calculated by Merger Arbitrage Limited . We analyze the attractiveness and profitability of each spread going forward and indicate the trading positio...
Merger activity increased last week with four new deals announced and five pending deals closing. Deal Statistics New Deals The acquisition of TIER REIT (TIER) by Cousins Properties Incorporated (CUZ) for $2.38 billion in an all stock deal. Under the terms of the agreement, Cous...
News, Short Squeeze, Breakout and More Instantly...
Celgene Corporation Company Name:
CELG Stock Symbol:
NASDAQ Market:
In this clip from "The Pharma & Biotech Show" on Motley Fool Live , recorded on Feb. 2 , Motley Fool contributor Brian Orelli analyzes Gilead 's (NASDAQ: GILD) earnings report and discusses why the biotech giant could see fairly low revenue growth or even see earnings dr...
What coronavirus? Amgen 's (NASDAQ: AMGN) latest set of quarterly figures, delivered Tuesday, showed growth in the company's fundamentals during a challenging time for companies across all economic sectors. The veteran biotech company booked revenue of nearly $6.21 billion in the second qu...
It's scary out there right now for investors, with wild market swings and a lot of negative news coming out of quarterly reports. There is one sector, however, that will survive and likely thrive despite the coronavirus pandemic shutdown -- healthcare. That said, investors shouldn't head for jus...